You Huang
ABSTRACT
Human epidermal growth factor receptor (HER) family belongs to the transmembrane protein receptor family of the tyrosine kinase I subfamily and has been determined to be closely related to the clinicopathological characteristics of various tumors and the poor prognosis of tumor patients. However, the different expression patterns of the four HER family genes and their correlation with cancer immune infiltrate have not been analyzed. In this article, we analyzed the expression level of the HER family in breast cancer patients through Oncomine and Interactive Analysis of Gene Expression Profiles (GEPIA). We found that the expression levels of ERBB2 and ERBB3 in invasive breast cancer (BCRA) tissues were higher than those in normal breast tissues, while the expression levels of EGFR in the former were lower than those in the latter. Using the Tumor Immunity Estimation Resource (TIMER) database to study the correlation between the HER family and breast cancer immune infiltrates shows that the expression of the HER family is significantly associated with tumor purity and the level of infiltration of various immune cells. This study laid the foundation for further exploration of the molecular mechanism of the HER family in breast cancer.
- Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, Znaor A and Bray FJIjoc. 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. 144: 1941-1953.Google Scholar
- Velaei K, Samadi N, Barazvan B and Soleimani Rad JJB. 2016. Tumor microenvironment-mediated chemoresistance in breast cancer. 30: 92-100.Google Scholar
- Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J, He X and Perou CJBcrB. 2010. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. 12: R68.Google Scholar
- Lee W and Boyer TJL. 2001. BRCA1 and BRCA2 in breast cancer. S5.Google Scholar
- Balaji K, Subramanian B, Yadav P, Anu Radha C and Ramasubramanian V. 2016. Radiation therapy for breast cancer: Literature review. Med Dosim. 41: 253-257.Google ScholarCross Ref
- Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso FJNrDp. 2019. Breast cancer. Nat Rev Dis Primers.5: 66.Google ScholarCross Ref
- Ramakrishna N, Temin S, Chandarlapaty S, Crews J, Davidson N, Esteva F, Giordano S, Kirshner J, Krop I, Levinson J, Modi S, Patt D, Perlmutter J, Winer E and Lin NJJocoojotASoCO. 2018. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. 36: 2804-2807.Google Scholar
- Finigan JH, Downey GP and Kern JA. 2012. Human epidermal growth factor receptor signaling in acute lung injury. Am J Respir Cell Mol Biol. 47: 395-404.Google ScholarCross Ref
- Wee P and Wang Z. 2017. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) 9:Google Scholar
- Roskoski R, Jr. 2014. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 79: 34-74.Google ScholarCross Ref
- Nuciforo P, Radosevic-Robin N, Ng T and Scaltriti M. 2015. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 17: 53.Google ScholarCross Ref
- Khelwatty SA, Essapen S, Bagwan I, Green M, Seddon AM and Modjtahedi H. 2014. Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival. PLoS One 9: e91139.Google ScholarCross Ref
- Yamaguchi H, Chang SS, Hsu JL and Hung MC. 2014. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 33: 1073-1081.Google ScholarCross Ref
- Carrasco-García E, Saceda M and Martínez-Lacaci I. 2014. Role of receptor tyrosine kinases and their ligands in glioblastoma. Cells. 3: 199-235.Google ScholarCross Ref
- King CR, Kraus MH and Aaronson SA. 1985. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 229: 974-976.Google ScholarCross Ref
- Harari D and Yarden Y. 2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 19: 6102-6114.Google ScholarCross Ref
- Luhtala S, Staff S, Kallioniemi A, Tanner M and Isola J. 2018. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer. BMC Cancer. 18: 1045.Google ScholarCross Ref
- Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B and Earp HS, 3rd. 2001. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 21: 4265-4275.Google ScholarCross Ref
- Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA, Jr., McCall W, Sgagias MK, Cowan KH and Earp HS, 3rd. 2006. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol. 26: 6412-6424.Google ScholarCross Ref
- Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D and Chinnaiyan AM. 2007. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 9: 166-180.Google ScholarCross Ref
- Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z. 2017. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 45: W98-w102.Google ScholarCross Ref
- Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B and Varambally. 2017. S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 19: 649-658.Google ScholarCross Ref
- Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, Fall J, Gatto L, Gnann C, Hober S, Hjelmare M, Johansson F, Lee S, Lindskog C, Mulder J, Mulvey CM, Nilsson P, Oksvold P, Rockberg J, Schutten R, Schwenk JM, Sivertsson Å, Sjöstedt E, Skogs M, Stadler C, Sullivan DP, Tegel H, Winsnes C, Zhang C, Zwahlen M, Mardinoglu A, Pontén F, von Feilitzen K, Lilley KS, Uhlén M and Lundberg E. 2017. A subcellular map of the human proteome. Science. 356.Google Scholar
- Comprehensive molecular portraits of human breast tumours. 2012. Nature. 490: 61-70.Google Scholar
- Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS. 2017. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 77: e108-e110.Google ScholarCross Ref
- Sergina NV and Moasser MM. 2007. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 13: 527-534.Google ScholarCross Ref
- Howe LR and Brown PH. 2017. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 4: 1149-1157.Google ScholarCross Ref
- Yang L, Li Y, Bhattacharya A and Zhang Y. 2019. A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer. Sci Transl Med. 11.Google Scholar
- Martinelli E, De Palma R, Orditura M, De Vita F and Ciardiello F. 2009. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 158: 1-9.Google ScholarCross Ref
- Kaumaya PT and Foy KC. 2012. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 8: 961-987.Google ScholarCross Ref
- Sakhdari A, Hutchinson L and Cosar E F. 2015. Molecular Pathology of HER Family of Oncogenes in Breast Cancer: HER-2 Evaluation and Role in Targeted Therapy. Springer New York. 119-136Google Scholar
- Ueno N and Zhang DJJoC. 2011. Targeting EGFR in Triple Negative Breast Cancer. 2: 324-328.Google Scholar
- Nakai K, Hung MC and Yamaguchi H. 2016. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 6: 1609-1623.Google Scholar
- Masuda H, Zhang D, Bartholomeusz C, Doihara H, Hortobagyi GN and Ueno NT. 2012. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 136: 331-345.Google ScholarCross Ref
- Sanders SH, Brena SF, Spier CJ, Beltrutti D, McConnell H and Quintero O. 1992. Chronic low back pain patients around the world: cross-cultural similarities and differences. Clin J Pain. 8: 317-323.Google ScholarCross Ref
- Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, Köchli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R and Sauter G. 2004. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64: 8534-8540.Google ScholarCross Ref
- Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK. 2012. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 16: 15-31.Google ScholarCross Ref
- Ali R and Wendt MK. 2017. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2: 16042-.Google ScholarCross Ref
- Kauraniemi P and Kallioniemi A. 2006. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr Relat Cancer. 13: 39-49.Google ScholarCross Ref
- Harbeck N. 2018. Advances in targeting HER2-positive breast cancer. Curr Opin Obstet Gynecol. 30: 55-59.Google ScholarCross Ref
- Marchese A. 2006. Assessment of degradation and ubiquitination of CXCR4, a GPCR regulated by EGFR family members. Methods Mol Biol. 327: 139-145.Google Scholar
- Ballard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML and Allison KH. 2017. 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol. 30: 227-235.Google ScholarCross Ref
- Pernas S, Barroso-Sousa R and Tolaney SM. 2018. Optimal treatment of early stage HER2-positive breast cancer. Cancer. 124: 4455-4466.Google ScholarCross Ref
- Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Jr., Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M and Jackisch C. 2017. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 389: 1195-1205.Google ScholarCross Ref
- Du F, Yuan P, Zhao ZT, Yang Z, Wang T, Zhao JD, Luo Y, Ma F, Wang JY, Fan Y, Cai RG, Zhang P, Li Q, Song YM and Xu BH. 2016. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment. Sci Rep. 6: 33825.Google ScholarCross Ref
- Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA and Jain RK. 2017. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Sci Transl Med. 9:Google Scholar
- Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S and Brockhoff G. 2008. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 10: R2.Google ScholarCross Ref
- Lyu H, Han A, Polsdofer E, Liu S and Liu B. 2018. Understanding the biology of HER3 receptor as a therapeutic target in human cancer. Acta Pharm Sin B. 8: 503-510.Google ScholarCross Ref
- Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, Baselga J, Scaltriti M and Mahmood U. 2016. Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. J Nucl Med. 57: 1413-1419.Google ScholarCross Ref
- Longo JF, Brosius SN, Black L, Worley SH, Wilson RC, Roth KA and Carroll SL. 2019. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms. Cell Commun Signal. 17: 74.Google ScholarCross Ref
- Dey N, Williams C, Leyland-Jones B and De P. 2015. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 7: 733-750.Google Scholar
- Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N and Moasser MM. 2018. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 78: 3645-3658.Google ScholarCross Ref
- Khalil HS, Langdon SP, Kankia IH, Bown J and Deeni YY. 2016. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies. Oxid Med Cell Longev. 2016: 4148791.Google ScholarCross Ref
- Xiao Y, Li Y, Tao H, Humphries B, Li A, Jiang Y, Yang C, Luo R and Wang Z. 2018. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Lett. 433: 199-209.Google ScholarCross Ref
- Wang J, Yin J, Yang Q, Ding F, Chen X, Li B and Tian X. 2016. Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis. Oncotarget. 7: 76693-76703.Google ScholarCross Ref
- Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM and Jones FE. 2006. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer Res. 66: 6412-6420Google ScholarCross Ref
- Kim JY, Jung HH, Do IG, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH and Im YH. 2016. Prognostic value of ERBB4 expression in patients with triple negative breast cancer. BMC Cancer. 16: 138.Google ScholarCross Ref
- Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS and Kurokawa M. 2015. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Cell Cycle. 14: 648-655.Google ScholarCross Ref
Recommendations
Prognosis Analysis of Breast Cancer Based on DO-UniBIC Gene Screening Method
Web Information Systems and ApplicationsAbstractA DO-UniBIC gene screening method was proposed. Firstly, Disease Ontology (DO) analysis was used to screen out breast cancer related genes from differentially expressed genes, and then UniBIC algorithm was used to find all gene clusters with the ...
Prognostic Factor Analysis for Breast Cancer Using Gene Expression Profiles
DTMBIO '15: Proceedings of the ACM Ninth International Workshop on Data and Text Mining in Biomedical InformaticsThe survival of patients with breast cancer is highly sporadic, from a few months to more than 15 years. Recently, the large-scale gene expression profiling of tumors has been used as a promising means of predicting prognosis factors. In this study, we ...
Prognosis Prediction of Breast Cancer Based on CGAN
Web Information Systems and ApplicationsAbstractBreast cancer is the malignancy with the highest morbidity and mortality rate in women worldwide, and prognosis prediction of breast cancer is of great practical importance for both patients and clinical practitioners. In this paper, we use a ...
Comments